Role of peroxisome proliferator-activated receptor-γ in vascular muscle in the cerebral circulation

Hypertension

Volumn 64, Issue 5, 2014, Pages 1088-1093

  De Silva, T Michael ^a   Modrick, Mary L ^a   Ketsawatsomkron, Pimonrat ^a   Lynch, Cynthia ^a   Chu, Yi ^a   Pelham, Christopher J ^a   Sigmund, Curt D ^a   Faraci, Frank M ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b Iowa City Veterans Affairs Health Care System   (United States)

Author keywords

Cerebral arteries; Microcirculation; Nitric oxide; Small vessel disease

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACETYLCHOLINE; ANGIOTENSIN; ARACHIDONIC ACID; BARIUM; CROMAKALIM; MYOSIN HEAVY CHAIN; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RHO KINASE; SEROTONIN; VASOCONSTRICTOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASILAR ARTERY; BLOOD VESSEL TONE; BRAIN ARTERY; BRAIN BLOOD FLOW; BRAIN CAPILLARY; BRAIN CIRCULATION; BRAIN MICROCIRCULATION; CAROTID ARTERY; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MESENTERIC ARTERY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; RESISTANCE BLOOD VESSEL; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION; VASOMOTOR REFLEX; ANIMAL; ARTERIOLE; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MUTANT MOUSE STRAIN; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; ARTERIOLES; CEREBROVASCULAR CIRCULATION; FEMALE; HUMANS; MALE; MICE; MICE, MUTANT STRAINS; MICE, TRANSGENIC; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; PPAR GAMMA; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; VASODILATION;

EID: 84925770086     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03935     Document Type: Article

References (33)

1. Ketsawatsomkron P, Pelham CJ, Groh S, Keen HL, Faraci FM, Sigmund CD. Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature? J Biol Chem. 2010;285:9311-9316.
2. Marchesi C, Schiffrin EL. Peroxisome proliferator-activated receptors and the vascular system: beyond their metabolic effects. J Am Soc Hypertens. 2008;2:227-238.
3. Plutzky J. The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. Circ Res. 2011;108:1002-1016.
4. Davidson M, Meyer PM, Haffner S, Feinstein S, D'Agostino R, Sr, Kondos GT, Perez A, Chen Z, Mazzone T. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation. 2008;117:2123-2130.
5. Peraza MA, Burdick AD, Marin HE, Gonzalez FJ, Peters JM. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol Sci. 2006;90:269-295.
6. Heikkinen S, Auwerx J, Argmann CA. PPARgamma in human and mouse physiology. Biochim Biophys Acta. 2007;1771:999-1013.
7. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402:880-883.
8. Tsai YS, Kim HJ, Takahashi N, Kim HS, Hagaman JR, Kim JK, Maeda N. Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma. J Clin Invest. 2004;114:240-249.
9. Beyer AM, Baumbach GL, Halabi CM, Modrick ML, Lynch CM, Gerhold TD, Ghoneim SM, de Lange WJ, Keen HL, Tsai YS, Maeda N, Sigmund CD, Faraci FM. Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling. Hypertension. 2008;51:867-871.
10. Halabi CM, Beyer AM, de Lange WJ, Keen HL, Baumbach GL, Faraci FM, Sigmund CD. Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab. 2008;7:215-226.
11. Alexis JD, Wang N, Che W, Lerner-Marmarosh N, Sahni A, Korshunov VA, Zou Y, Ding B, Yan C, Berk BC, Abe J. Bcr kinase activation by angiotensin II inhibits peroxisome-proliferator-activated receptor gamma transcriptional activity in vascular smooth muscle cells. Circ Res. 2009;104:69-78.
12. Ketsawatsomkron P, Lorca RA, Keen HL, Weatherford ET, Liu X, Pelham CJ, Grobe JL, Faraci FM, England SK, Sigmund CD. PPARγ regulates resistance vessel tone through a mechanism involving RGS5-mediated control of protein kinase C and BKCa channel activity. Circ Res. 2012;111:1446-1458.
13. Faraci FM. Protecting against vascular disease in brain. Am J Physiol Heart Circ Physiol. 2011;300:H1566-H1582.
14. Faraci FM, Heistad DD. Regulation of the cerebral circulation: role of endothelium and potassium channels. Physiol Rev. 1998;78:53-97.
15. Katusic ZS, Austin SA. Endothelial nitric oxide: protector of a healthy mind. Eur Heart J. 2014;35:888-894.
16. Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80:844-866.
17. Faraci FM, Modrick ML, Lynch CM, Didion LA, Fegan PE, Didion SP. Selective cerebral vascular dysfunction in Mn-SOD-deficient mice. J Appl Physiol (1985). 2006;100:2089-2093.
18. Sobey CG, Faraci FM. Effects of a novel inhibitor of guanylyl cyclase on dilator responses of mouse cerebral arterioles. Stroke. 1997;28:837-842, discussion 842.
19. Dunn KM, Nelson MT. Potassium channels and neurovascular coupling. Circ J. 2010;74:608-616.
20. Knot HJ, Zimmermann PA, Nelson MT. Extracellular K(+)-induced hyperpolarizations and dilatations of rat coronary and cerebral arteries involve inward rectifier K(+) channels. J Physiol. 1996;492 (Pt 2):419-430.
21. Budzyn K, Marley PD, Sobey CG. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol Sci. 2006;27:97-104.
22. Sawada N, Liao JK. Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis. Antioxid Redox Signal. 2014;20:1251-1267.
23. Wakino S, Hayashi K, Kanda T, Tatematsu S, Homma K, Yoshioka K, Takamatsu I, Saruta T. Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2. Circ Res. 2004;95:e45-e55.
24. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270:12953-12956.
25. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol. 1999;19:546-551.
26. Cipolla MJ, Bishop N, Vinke RS, Godfrey JA. PPAR{gamma} activation prevents hypertensive remodeling of cerebral arteries and improves vascular function in female rats. Stroke. 2010;41:1266-1270.
27. Roberts TJ, Chapman AC, Cipolla MJ. PPAR-gamma agonist rosiglitazone reverses increased cerebral venous hydraulic conductivity during hypertension. Am J Physiol Heart Circ Physiol. 2009;297:H1347-H1353.
28. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD. PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension. 2004;43:661-666.
29. Pelham CJ, Ketsawatsomkron P, Groh S, Grobe JL, de Lange WJ, Ibeawuchi SR, Keen HL, Weatherford ET, Faraci FM, Sigmund CD. Cullin-3 regulates vascular smooth muscle function and arterial blood pressure via PPARγ and RhoA/Rho-kinase. Cell Metab. 2012;16:462-472.
30. Chang L, Villacorta L, Zhang J, Garcia-Barrio MT, Yang K, Hamblin M, Whitesall SE, D'Alecy LG, Chen YE. Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension. Circulation. 2009;119:2161-2169.
31. Faraco G, Moraga A, Moore J, Anrather J, Pickel VM, Iadecola C. Circulating endothelin-1 alters critical mechanisms regulating cerebral microcirculation. Hypertension. 2013;62:759-766.
32. Richardson BT, Dibble CF, Borikova AL, Johnson GL. Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling. Biol Chem. 2013;394:35-42.
33. Kajikawa M, Noma K, Maruhashi T, Mikami S, Iwamoto Y, Iwamoto A, Matsumoto T, Hidaka T, Kihara Y, Chayama K, Nakashima A, Goto C, Liao JK, Higashi Y. Rho-associated kinase activity is a predictor of cardiovascular outcomes. Hypertension. 2014;63:856-864.